ArticleProceedings of the National Academy of Sciences of the United States of America2013
A nanoparticle formulation that selectively transfects metastatic tumors in mice.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 65 citations in OpenAlex.
- Extracellular RNAs in Liquid Biopsy: Applications in MASLD and MASH Diagnosis and Monitoring.Diagnostics (Basel, Switzerland) · 2025Review
- Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2.eLife · 2024Article
- Mechanisms and Delivery of tRNA Therapeutics.Chemical reviews · 2024Review
- Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?International journal of molecular sciences · 2021Review
- Data-Driven Modeling of the Cellular Pharmacokinetics of Degradable Chitosan-Based Nanoparticles.Nanomaterials (Basel, Switzerland) · 2021Article
- Small interfering RNA for cancer treatment: overcoming hurdles in delivery.Acta pharmaceutica Sinica. B · 2020Review
- In vivo gene delivery mediated by non-viral vectors for cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Nanoparticles in Gastrooncology.Visceral medicine · 2020Review
- VTIQ evaluates antitumor effects of NET-1 siRNA by UTMD in HCC xenograft models.Oncology letters · 2018Article
- Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo.International journal of pharmaceutics · 2018Article
- Continuous Production of Discrete Plasmid DNA-Polycation Nanoparticles Using Flash Nanocomplexation.Small (Weinheim an der Bergstrasse, Germany) · 2016Article
- Targeted nanoparticles for colorectal cancer.Nanomedicine (London, England) · 2016Review
- New polymer of lactic-co-glycolic acid-modified polyethylenimine for nucleic acid delivery.Nanomedicine (London, England) · 2016Article
- Critical Length of PEG Grafts on lPEI/DNA Nanoparticles for Efficient in Vivo Delivery.ACS biomaterials science & engineering · 2016Article
- Rapid endosomal escape of prickly nanodiamonds: implications for gene delivery.Scientific reports · 2015Article
- Highly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the Brain.Advanced healthcare materials · 2015Article
- Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Bioreducible polycations in nucleic acid delivery: past, present, and future trends.Macromolecular bioscience · 2014Review
- Bench-to-bedside translation of magnetic nanoparticles.Nanomedicine (London, England) · 2014Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Nanoparticle gene therapy holds great promise for the treatment of malignant disease in light of the large number of potent, tumor-specific therapeutic payloads potentially available for delivery. To be effective, gene therapy vehicles must be able to deliver their therapeutic payloads to metastatic lesions after systemic administration. Here we describe nanoparticles comprised of a core of high molecular weight linear polyethylenimine (LPEI) complexed with DNA and surrounded by a shell of polyethyleneglycol-modified (PEGylated) low molecular weight LPEI. Compared with a state-of-the-art commercially available in vivo gene delivery formulation, i.v. delivery of the core/PEGylated shell (CPS) nanoparticles provided more than a 16,000-fold increase in the ratio of tumor to nontumor transfection. The vast majority of examined liver and lung metastases derived from a colorectal cancer cell line showed transgene expression after i.v. CPS injection in an animal model of metastasis. Histological examination of tissues from transfected mice revealed that the CPS nanoparticles selectively transfected neoplastic cells rather than stromal cells within primary and metastatic tumors. However, only a small fraction of neoplastic cells (<1%) expressed the transgene, and the extent of delivery varied with the tumor cell line, tumor site, and host mouse strain used. Our results demonstrate that these CPS nanoparticles offer substantial advantages over previously described formulations for in vivo nanoparticle gene therapeutics. At the same time, they illustrate that major increases in the effectiveness of such approaches are needed for utility in patients with metastatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.